Thomas Damgaard Sandahl

Liver-related effects of chronic hepatitis C antiviral treatment

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Standard

Liver-related effects of chronic hepatitis C antiviral treatment. / Laursen, Tea L.; Sandahl, Thomas D.; Kazankov, Konstantin et al.

In: World Journal of Gastroenterology, Vol. 26, No. 22, 06.2020, p. 2931-2947.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Laursen TL, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology. 2020 Jun;26(22):2931-2947. doi: 10.3748/wjg.v26.i22.2931

Author

Laursen, Tea L. ; Sandahl, Thomas D. ; Kazankov, Konstantin et al. / Liver-related effects of chronic hepatitis C antiviral treatment. In: World Journal of Gastroenterology. 2020 ; Vol. 26, No. 22. pp. 2931-2947.

Bibtex

@article{f4af751c29aa4065af97b994f6d5791c,
title = "Liver-related effects of chronic hepatitis C antiviral treatment",
abstract = "More than five years ago, the treatment of hepatitis C virus infection was revolutionized with the introduction of all-oral direct-acting antiviral (DAA) drugs. They proved highly efficient in curing patients with chronic hepatitis C (CHC), including patients with cirrhosis. The new DAA treatments were alleged to induce significant improvements in clinical outcome and prognosis, but the exact cause of the expected benefit was unclear. Further, little was known about how the underlying liver disease would be affected during and after viral clearance. In this review, we describe and discuss the liver-related effects of the new treatments in regards to both pathophysiological aspects, such as macrophage activation, and the time-dependent effects of therapy, with specific emphasis on inflammation, structural liver changes, and liver function, as these factors are all related to morbidity and mortality in CHC patients. It seems clear that antiviral therapy, especially the achievement of a sustained virologic response has several beneficial effects on liver-related parameters in CHC patients with advanced liver fibrosis or cirrhosis. There seems to be a time-dependent effect of DAA therapy with viral clearance and the resolution of liver inflammation followed by more discrete changes in structural liver lesions. These improvements lead to favorable effects on liver function, followed by an improvement in cognitive dysfunction and portal hypertension. Overall, the data provide knowledge on the several beneficial effects of DAA therapy on liver-related parameters in CHC patients suggesting short- and long-term improvements in the underlying disease with the promise of an improved long-term prognosis.",
keywords = "Antiviral treatment, Chronic hepatitis C, Galactose elimination capacity, Hepatic encephalopathy, Inflammation, Liver cirrhosis, Liver fibrosis, Metabolic liver function, Portal hypertension, Urea synthesis capacity",
author = "Laursen, {Tea L.} and Sandahl, {Thomas D.} and Konstantin Kazankov and Jacob George and Henning Gr{\o}nb{\ae}k",
year = "2020",
month = jun,
doi = "10.3748/wjg.v26.i22.2931",
language = "English",
volume = "26",
pages = "2931--2947",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "Baishideng Publishing Group Co., Limited",
number = "22",

}

RIS

TY - JOUR

T1 - Liver-related effects of chronic hepatitis C antiviral treatment

AU - Laursen, Tea L.

AU - Sandahl, Thomas D.

AU - Kazankov, Konstantin

AU - George, Jacob

AU - Grønbæk, Henning

PY - 2020/6

Y1 - 2020/6

N2 - More than five years ago, the treatment of hepatitis C virus infection was revolutionized with the introduction of all-oral direct-acting antiviral (DAA) drugs. They proved highly efficient in curing patients with chronic hepatitis C (CHC), including patients with cirrhosis. The new DAA treatments were alleged to induce significant improvements in clinical outcome and prognosis, but the exact cause of the expected benefit was unclear. Further, little was known about how the underlying liver disease would be affected during and after viral clearance. In this review, we describe and discuss the liver-related effects of the new treatments in regards to both pathophysiological aspects, such as macrophage activation, and the time-dependent effects of therapy, with specific emphasis on inflammation, structural liver changes, and liver function, as these factors are all related to morbidity and mortality in CHC patients. It seems clear that antiviral therapy, especially the achievement of a sustained virologic response has several beneficial effects on liver-related parameters in CHC patients with advanced liver fibrosis or cirrhosis. There seems to be a time-dependent effect of DAA therapy with viral clearance and the resolution of liver inflammation followed by more discrete changes in structural liver lesions. These improvements lead to favorable effects on liver function, followed by an improvement in cognitive dysfunction and portal hypertension. Overall, the data provide knowledge on the several beneficial effects of DAA therapy on liver-related parameters in CHC patients suggesting short- and long-term improvements in the underlying disease with the promise of an improved long-term prognosis.

AB - More than five years ago, the treatment of hepatitis C virus infection was revolutionized with the introduction of all-oral direct-acting antiviral (DAA) drugs. They proved highly efficient in curing patients with chronic hepatitis C (CHC), including patients with cirrhosis. The new DAA treatments were alleged to induce significant improvements in clinical outcome and prognosis, but the exact cause of the expected benefit was unclear. Further, little was known about how the underlying liver disease would be affected during and after viral clearance. In this review, we describe and discuss the liver-related effects of the new treatments in regards to both pathophysiological aspects, such as macrophage activation, and the time-dependent effects of therapy, with specific emphasis on inflammation, structural liver changes, and liver function, as these factors are all related to morbidity and mortality in CHC patients. It seems clear that antiviral therapy, especially the achievement of a sustained virologic response has several beneficial effects on liver-related parameters in CHC patients with advanced liver fibrosis or cirrhosis. There seems to be a time-dependent effect of DAA therapy with viral clearance and the resolution of liver inflammation followed by more discrete changes in structural liver lesions. These improvements lead to favorable effects on liver function, followed by an improvement in cognitive dysfunction and portal hypertension. Overall, the data provide knowledge on the several beneficial effects of DAA therapy on liver-related parameters in CHC patients suggesting short- and long-term improvements in the underlying disease with the promise of an improved long-term prognosis.

KW - Antiviral treatment

KW - Chronic hepatitis C

KW - Galactose elimination capacity

KW - Hepatic encephalopathy

KW - Inflammation

KW - Liver cirrhosis

KW - Liver fibrosis

KW - Metabolic liver function

KW - Portal hypertension

KW - Urea synthesis capacity

UR - http://www.scopus.com/inward/record.url?scp=85087140724&partnerID=8YFLogxK

U2 - 10.3748/wjg.v26.i22.2931

DO - 10.3748/wjg.v26.i22.2931

M3 - Review

C2 - 32587440

AN - SCOPUS:85087140724

VL - 26

SP - 2931

EP - 2947

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 22

ER -